Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $256 to $253.
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $256 to $253.